✦ LIBER ✦

1237 POSTER WIN55,212-2 as a Potential Treatment for Estrogen-receptor Negative Breast Cancer

✍ Scribed by K. Tran; M. Nimick; S. Taurin; B. Yadav; R.J. Rosengren

Book ID: 117661343
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 57 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(11)70849-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Calcium Channel TRPV6 as a Potential The

Calcium Channel TRPV6 as a Potential Therapeutic Target in Estrogen Receptor-Negative Breast Cancer

✍ Peters, A. A.; Simpson, P. T.; Bassett, J. J.; Lee, J. M.; Da Silva, L.; Reid, L 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 680 KB

Androgen receptor as a target for the tr

Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory

✍ Nahleh, Zeina 📂 Article 📅 2008 🏛 Future Medicine 🌐 English ⚖ 167 KB

Fluorine-Substituted Cyclofenil Derivati

Fluorine-Substituted Cyclofenil Derivatives as Estrogen Receptor Ligands: Synthesis and Structure−Affinity Relationship Study of Potential Positron Emission Tomography Agents for Imaging Estrogen Receptors in Breast Cancer

✍ Seo, Jai Woong; Comninos, John S.; Chi, Dae Yoon; Kim, Dong Wook; Carlson, Kathr 📂 Article 📅 2006 🏛 American Chemical Society 🌐 English ⚖ 456 KB

New iodinated progestins as potential li

New iodinated progestins as potential ligands for progesterone receptor imaging in breast cancer. part 2: in vivo pharmacological characterization

✍ Leonie J.M Rijks; Jan C van den Bos; Peter A.P.M van Doremalen; Gerard J Boer; K 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 316 KB

An European Organisation for Research an

An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for Human Epidermal Growth Factor Receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer

✍ Bonnefoi, H.; Zaman, K.; Debled, M.; Fiche, M.; Fournier, M.; Nobahar, M.; Pierg 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 397 KB

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB